Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

492 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effectiveness of first-line abiraterone versus enzalutamide among patients ≥80 years of age with metastatic castration-resistant prostate cancer: A retrospective propensity score-weighted comparative cohort study.
Soleimani M, Zou K, Sunderland K, Struss W, Eigl BJ, Nappi L, Kollmannsberger CK, Finch D, Noonan K, Vergidis J, Zulfiqar M, Chi KN, Khalaf DJ. Soleimani M, et al. Among authors: noonan k. Eur J Cancer. 2021 Jul;152:215-222. doi: 10.1016/j.ejca.2021.05.003. Epub 2021 Jun 12. Eur J Cancer. 2021. PMID: 34130153
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.
Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, Coskinas X, Frydenberg M, Hague WE, Horvath LG, Joshua AM, Lawrence NJ, Marx G, McCaffrey J, McDermott R, McJannett M, North SA, Parnis F, Parulekar W, Pook DW, Reaume MN, Sandhu SK, Tan A, Tan TH, Thomson A, Tu E, Vera-Badillo F, Williams SG, Yip S, Zhang AY, Zielinski RR, Sweeney CJ; ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Davis ID, et al. N Engl J Med. 2019 Jul 11;381(2):121-131. doi: 10.1056/NEJMoa1903835. Epub 2019 Jun 2. N Engl J Med. 2019. PMID: 31157964 Clinical Trial.
Controversial issues in the management of patients with advanced prostate cancer: Results from a Canadian consensus forum.
Saad F, Canil C, Finelli A, Hotte SJ, Malone S, Shayegan B, So AI, Aaron L, Basappa NS, Conter HJ, Danielson B, Gotto G, Hamilton RJ, Izard JP, Kapoor A, Kolinsky M, Lalani AA, Lattouf JB, Morash C, Morgan SC, Niazi T, Noonan KL, Ong M, Rendon RA, Sehdev S, Hew H, Park-Wyllie L, Chi KN. Saad F, et al. Can Urol Assoc J. 2020 Apr;14(4):E137-E149. doi: 10.5489/cuaj.6082. Epub 2019 Nov 5. Can Urol Assoc J. 2020. PMID: 31702544 Free PMC article. Review.
Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial.
Khalaf DJ, Annala M, Taavitsainen S, Finch DL, Oja C, Vergidis J, Zulfiqar M, Sunderland K, Azad AA, Kollmannsberger CK, Eigl BJ, Noonan K, Wadhwa D, Attwell A, Keith B, Ellard SL, Le L, Gleave ME, Wyatt AW, Chi KN. Khalaf DJ, et al. Among authors: noonan k. Lancet Oncol. 2019 Dec;20(12):1730-1739. doi: 10.1016/S1470-2045(19)30688-6. Epub 2019 Nov 11. Lancet Oncol. 2019. PMID: 31727538 Clinical Trial.
Real-world management of advanced prostate cancer: A description of management practices of community-based physicians and prostate cancer specialists.
Hotte SJ, Finelli A, Chi KN, Canil C, Fleshner N, Kapoor A, Kolinsky M, Malone S, Morash C, Niazi T, Noonan KL, Ong M, Pouliot F, Shayegan B, So AI, Sorabji D, Hew H, Park-Wyllie L, Saad F. Hotte SJ, et al. Can Urol Assoc J. 2021 Feb;15(2):E90-E96. doi: 10.5489/cuaj.6779. Can Urol Assoc J. 2021. PMID: 32853135 Free PMC article.
Results from a Canadian consensus forum of key controversial areas in the management of advanced prostate cancer: Recommendations for Canadian healthcare providers.
Saad F, Hotte SJ, Finelli A, Malone S, Niazi T, Noonan K, Shayegan B, So AI, Danielson B, Basappa NS, Cagiannos I, Canil C, Delouya G, Fernandes R, Ferrario C, Gotto GT, Hamilton RJ, Izard JP, Kapoor A, Khalaf D, Kolinsky M, Lalani AK, Lavallée LT, Morash C, Morgan SC, Ong M, Pouliot F, Rendon RA, Yip S, Zardan A, Park-Wyllie L, Chi K. Saad F, et al. Among authors: noonan k. Can Urol Assoc J. 2021 Oct;15(10):353-358. doi: 10.5489/cuaj.7347. Can Urol Assoc J. 2021. PMID: 34125066 Free PMC article. Review.
Real-World Use of Androgen-Deprivation Therapy: Intensification Among Older Canadian Men With de Novo Metastatic Prostate Cancer.
Wallis CJD, Malone S, Cagiannos I, Morgan SC, Hamilton RJ, Basappa NS, Ferrario C, Gotto GT, Fernandes R, Niazi T, Noonan KL, Saad F, Hotte SJ, Hew H, Chan KFY, Wyllie LP, Shayegan B. Wallis CJD, et al. JNCI Cancer Spectr. 2021 Oct 1;5(6):pkab082. doi: 10.1093/jncics/pkab082. eCollection 2021 Dec. JNCI Cancer Spectr. 2021. PMID: 34926988 Free PMC article.
Real-world use of systemic therapies in men with metastatic castration resistant prostate cancer (mCRPC) in Canada.
Shayegan B, Wallis CJD, Malone S, Cagiannos I, Hamilton RJ, Ferrario C, Gotto GT, Basappa NS, Morgan SC, Fernandes R, Morash C, Niazi T, Noonan KL, Rendon R, Osborne B, Park-Wyllie L, Chan KFY, Hotte SJ, Saad F. Shayegan B, et al. Urol Oncol. 2022 May;40(5):192.e1-192.e9. doi: 10.1016/j.urolonc.2022.01.009. Epub 2022 Feb 23. Urol Oncol. 2022. PMID: 35216890 Free article.
492 results